Abbreviation · Organisation
COC
Centre for Culture and Leisure — founded 1946, oldest LGBTQ+ umbrella organisation in the world.
2 min read · updated May 2026
COC Netherlands (founded in 1946) is the oldest surviving LGBTQ+ umbrella organisation in the world. Originally a gay emancipation organisation, COC has shifted since the 2010s toward a broader queer and trans agenda. It receives institutional funding from the Ministry of Education, Culture and Science (OCW) and is frequently consulted in policy development.
COC has spoken out in favour of self-identification, the ban on conversion therapy, and the expansion of transgender healthcare for young people.
Critical Analysis
COC's change of direction — from LGB emancipation to trans activism — has met resistance among part of its older membership. In England, the same shift at Stonewall led to the founding of the LGB Alliance, which defends the original narrow mandate. In the Netherlands, a comparable split has yet to emerge, but the tension between "gay rights" and "trans activism" is palpable within COC.
Related
Political Function of the Abbreviation
An abbreviation like COC is not a linguistic invention but a political instrument. Those who use the abbreviation simultaneously signal acceptance of the accompanying ideological framework: identity over biology, self-declaration over diagnosis, language over reality. Those who refuse to go along are accused of being outdated or hateful.
Resistance to that pressure does not come only from conservative quarters. Lesbian organisations, sports federations, women's rights organisations and clinicians are registering objections to the shifting of category boundaries. The abbreviation itself is often defended with the argument of inclusion, but in practice it compels the abandonment of categories that are precisely protective — for women, for lesbians, for children.
Medical Context and the Evidence
The medical side of the debate has shifted entirely within a few years. The Cass Review (2024) found that the evidence base for puberty blockers and cross-sex hormones in minors is weak. NHS England accordingly ceased routine prescribing. SBU (Sweden, 2022), COHERE (Finland, 2020), UKOM (Norway, 2023) and NICE (UK, 2020) reached the same conclusion.
In the communications of organisations that embrace COC and related terms, those reassessments are almost always absent. The impression of settled science is maintained by silence on the Cass Review and the Scandinavian reversal. The WPATH Files (2024) showed that even within WPATH, clinicians harbour uncertainty about informed consent in minors.
Consequences for Public Debate
Expanding abbreviations is not without cost. Each new letter comes with a claim to recognition in legislation, education and healthcare. Without evidence for the underlying category, policy is made as if the evidence exists. Those who ask questions receive not a substantive answer but moral condemnation.
Language drives policy. Those who accept the abbreviation implicitly accept the claim that all the identities it encompasses are equally valid and scientifically grounded. That is a political claim, not a linguistic one. Criticism of an abbreviation is not criticism of individuals — it is criticism of a framework that is increasingly placed beyond the reach of debate.
International Reassessment
Several national health authorities have in recent years distanced themselves from the gender-affirming model for minors. The common denominator: evidence of lasting benefits is lacking, while the risks are real.
Cass Review (2024). Review commissioned by NHS England, conducted by Hilary Cass. Conclusion: the evidence base for puberty blockers and cross-sex hormones in minors is weak. NHS England ceased routine prescribing of puberty blockers outside of a research setting.
SBU — Sweden (2022). The Swedish Agency for Health Technology Assessment (SBU) and Karolinska University Hospital ceased prescribing puberty blockers and hormones to minors outside of a research setting. Reason: evidence for effectiveness and safety is lacking.
NICE — United Kingdom (2020). Two evidence reviews by NICE (puberty blockers and cross-sex hormones) classified the evidence base as very low certainty. None of the identified studies met modern methodological standards.
COHERE — Finland (2020). The Finnish Council for Choices in Health Care revised the protocol: psychotherapy as the first-line approach, medical transition in minors only in exceptional cases and within a research setting.
UKOM — Norway (2023). The Norwegian UKOM classified transgender healthcare for minors as experimental; existing protocols do not meet the requirements for evidence-based care.
WPATH Files (2024). Internal discussions among WPATH clinicians show acknowledgement that informed consent in minors is problematic and that serious side effects (bone density, fertility, cognitive development) are insufficiently explained.